Scarica l'app Stockscreener
107.39
2.48%
-2.73
Dopo l'orario di chiusura:
107.39
Kymera Therapeutics Inc Borsa (KYMR) Ultime notizie
B.Riley reiterates Kymera Therapeutics stock rating on new trial data - Investing.com Canada
Kymera Therapeutics stock reports 465.2 percent revenue growth - AD HOC NEWS
JPMorgan Flags Kymera Therapeutics (KYMR) for Positive Catalyst Ahead of Phase 2b Trial Results - GuruFocus
KYMR Stock Clocks Best Day In Over 6 Months On Advancing Eczema Trial Timeline - Stocktwits
Kymera Therapeutics at Stifel forum: faster path for lead drug By Investing.com - Investing.com Australia
Goldman Sachs resumes Kymera Therapeutics stock coverage By Investing.com - Investing.com Australia
Goldman Sachs resumes Kymera Therapeutics stock coverage - Investing.com
KYMR Looks 178.8% Overvalued on GF Value™ - GuruFocus
Piper Sandler reiterates Kymera Therapeutics stock rating at $140 By Investing.com - Investing.com Canada
Kymera Therapeutics doses first participant in KT-485 Phase 1 trial - scanx.trade
KYMR Maintained by Stifel -- Price Target Raised to $152 - GuruFocus
Stifel raises Kymera Therapeutics price target on drug trial outlook By Investing.com - Investing.com Australia
Kymera Therapeutics stock gains as Stifel lifts its target - AD HOC NEWS
Stifel Nicolaus Forecasts Strong Price Appreciation for Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Stifel maintains Buy on Kymera Therapeutics, lifts price target to $152 - scanx.trade
Kymera Therapeutics, Inc. (KYMR) Stock Analysis: Unveiling a 17.82% Potential Upside for Biotech Enthusiasts - DirectorsTalk Interviews
(KYMR) Volatility Zones as Tactical Triggers - Stock Traders Daily
Bank of America Corp DE Takes Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics (KYMR) Slips to $117.75 as Shares Consolidate Below Recent ResistanceSkew Index - dars.gov.et
Kymera Therapeutics stock gains as biotech sector strength follows recent earnings - AD HOC NEWS
Kymera Therapeutics stock gains after Morgan Stanley conference highlights oral degrader pipeline - AD HOC NEWS
Kymera Therapeutics, Inc.Common Stock (Nasdaq:KYMR) Price Chart - The Chronicle-Journal
Kymera Therapeutics Is Maintained at Buy by B of A Securities - Moomoo
Kymera's Nello Mainolfi: Degrading Proteins to Beat Dupixent with a Pill - finance.biggo.com
Kymera Therapeutics at Morgan Stanley conference: oral degrader push By Investing.com - Investing.com Canada
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
KYMR Maintained by B of A Securities -- Price Target Raised to $144 - GuruFocus
BofA Securities Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $144 - moomoo.com
BofA raises Kymera Therapeutics price target on trial progress By Investing.com - Investing.com Canada
Understanding Momentum Shifts in (KYMR) - Stock Traders Daily
Kymera Therapeutics at citigroup summit: oral immunology push gains pace By Investing.com - Investing.com Canada
KYMR Upgraded by Wolfe Research -- Rating Raised to Outperform - GuruFocus
Squarepoint Ops LLC Raises Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics at Wells Fargo conference: oral pipeline gains pace By Investing.com - Investing.com South Africa
Kymera Therapeutics at Wells Fargo conference: oral pipeline gains pace - Investing.com
Fund giant T. Rowe Price holds a double-digit stake in Kymera (KYMR) - Stock Titan
Have Kymera Therapeutics Insiders Been Selling Stock? - simplywall.st
36,237 Shares in Kymera Therapeutics, Inc. $KYMR Purchased by Legal & General Group Plc - MarketBeat
Kymera Therapeutics chief legal officer Adams disposes of $744k in KYMR stock - Investing.com Nigeria
Kymera Therapeutics (NASDAQ:KYMR) Insider Brian Adams Sells 6,371 Shares of Stock - MarketBeat
Kymera (NASDAQ: KYMR) insider plans stock sale to cover taxes - Stock Titan
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Atlas Venture Life Science Advisors LLC Decreases Stock Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Can KT-621 Mark a Turning Point for Kymera Therapeutics? - The Globe and Mail
Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT) - theglobeandmail.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Braidwell LP Buys 40,604 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
21,058 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Jupiter Topco LLC - MarketBeat
Kymera Therapeutics to Participate in Upcoming September Investor Conferences - The Manila Times
Executive at Kymera Therapeutics (NASDAQ: KYMR) plans another stock sale after June trade of $4.4M - Stock Titan
Five September events will webcast Kymera live - Stock Titan
Man Group plc Makes New $2.19 Million Investment in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses - investingnews.com
A clinical trial testing an oral medicine for eczema has finished enrolling patients. Kymera expects topline data by year-end 2026. - Stock Titan
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):